Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 7th European Lung Cancer Conference (ELCC) took place in Geneva, Switzerland on 5-8 May 2017.

The program covered content relevant for medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians, and other medical professionals involved in the diagnosis, treatment and follow-up of lung cancer patients.

ELCC 2017

05–08 May 2017 | Geneva, Switzerland

ELCC 2017

05–08 May 2017 | Geneva, Switzerland

The 7th European Lung Cancer Conference (ELCC) took place in Geneva, Switzerland on 5-8 May 2017.

The program covered content relevant for medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians, and other medical professionals involved in the diagnosis, treatment and follow-up of lung cancer patients.

Exciting current topics in lung cancer 1:33
Exciting current topics in lung cancer
Solange Peters • 5 May 2017
Why is European Lung Cancer Conference so important? 0:47
Why is European Lung Cancer Conference so important?
Solange Peters
Increasing patient access to the latest treatments 2:43
Increasing patient access to the latest treatments
Solange Peters • 5 May 2017
Challenges and opportunities for patients with advanced NSCLC 1:46
Challenges and opportunities for patients with advanced NSCLC
Solange Peters • 5 May 2017
The open questions surrounding immunotherapy and targeted therapy in lung cancer 2:29
The open questions surrounding immunotherapy and targeted therapy in lung cancer
Solange Peters • 5 May 2017
The BIRCH trial data discussed by Dr Peters 1:10
The BIRCH trial data discussed by Dr Peters
Solange Peters • 5 May 2017
The LUME-BioNIS study and its aims 1:29
The LUME-BioNIS study and its aims
Keith Kerr • 5 May 2017
Biomarker testing in NSCLC 2:04
Biomarker testing in NSCLC
Keith Kerr • 5 May 2017
Current treatment landscape for neuroendocrine tumors 0:51
Current treatment landscape for neuroendocrine tumors
Keith Kerr • 5 May 2017
Evolving guidelines for molecular testing in lung cancer 1:48
Evolving guidelines for molecular testing in lung cancer
Fred Hirsch • 5 May 2017
Phase II study of Durvalumab for patients with NSCLC 1:13
Phase II study of Durvalumab for patients with NSCLC
David Gandara • 5 May 2017
Molecular tools for lung cancer therapies 1:15
Molecular tools for lung cancer therapies
Charles Swanton • 5 May 2017
Increasing treatment options for NSCLC 2:07
Increasing treatment options for NSCLC
David Gandara • 5 May 2017
Benefits of targeted therapeutics in Lung Cancer 2:09
Benefits of targeted therapeutics in Lung Cancer
David Carbone • 5 May 2017
ESMO guidelines for thymic cancer management 1:52
ESMO guidelines for thymic cancer management
Nicolas Girard • 5 May 2017
The genetic landscape of lung cancer 1:00
The genetic landscape of lung cancer
Martin Reck • 5 May 2017
The content of VJOncology is intended for healthcare professionals